ACM
ANIP icon

ADAR1 Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

ADAR1 Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,700
Closed -$101K – 221
2024
Q3 		$101K Buy
+1,700
New +$104K 0.02% 187
2024
Q1 		– Sell
-2,400
Closed -$132K – 265
2023
Q4 		$132K Buy
+2,400
New +$132K 0.05% 91

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ADAR1 Capital Management's ANIP Position: Q4 2024 in Review

ADAR1 Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2024, closing a stake of 1,700 shares — an estimated $101K sold.

ADAR1 Capital Management first reported a position in ANIP in Q4 2023 and held it in 2 quarters. The position peaked at $132K in Q4 2023. 205 funds tracked by Wall St. Rank hold ANIP as of Q4 2024.

  • ADAR1 Capital Management reported no remaining ANI Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 1,700 ANI Pharmaceuticals shares in Q4 2024, an estimated $101K.
  • ADAR1 Capital Management first reported a position in ANI Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • ADAR1 Capital Management's ANI Pharmaceuticals position peaked at $132K in Q4 2023.
  • 205 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2024.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.